clarithromycin and tacrolimus

Clarithromycin is a potent inhibitor of CYP3A4, the enzyme responsible for tacrolimus metabolism. Inhibition of CYP3A4 markedly reduces tacrolimus clearance, leading to substantially elevated tacrolimus blood concentrations.

Elevated tacrolimus levels increase the risk of severe toxicity, including nephrotoxicity, neurotoxicity (e.g., tremor, headache, seizures), hyperglycaemia, and hypertension. The onset is usually within days of starting clarithromycin. There are documented cases of acute kidney injury and irreversible graft loss in transplant recipients.

Avoid co-prescription where possible. If unavoidable, consider a non-interacting macrolide (e.g., azithromycin) or another antibiotic. If the combination is necessary, reduce the tacrolimus dose (often by 50% or more), monitor trough levels frequently (e.g., every 2-3 days) and adjust based on levels. Monitor renal function, blood glucose, and signs of neurotoxicity.

This interaction is well established and is included in major interaction databases and drug labelling. Multiple case reports and pharmacokinetic studies consistently show increased tacrolimus concentrations, sometimes requiring dose reductions of 50-70%. Management is widely described in transplant guidelines.